Cliramitug clinical trials
Also written ALXN2220.
How each study uses cliramitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cliramitug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 5 · Other 0
Alexion Pharmaceuticals, Inc. (2) · Neurimmune AG (2) · AstraZeneca (1)
Studies
Open first, then newest update. How each study uses cliramitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid CardiomyopathyNot yet recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT07789483Written as ALXN2220
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CMActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06183931Written as ALXN2220
- Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMActive, not recruitingPhase 2Neurimmune AGNCT07213583Written as ALXN2220
- A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMActive, not recruitingPhase 2AstraZenecaNCT07608354Written as ALXN2220
- First-in-Human Study of NI006 in Patients With Amyloid Transthyretin CardiomyopathyCompletedPhase 1Neurimmune AGNCT04360434Written as NI006
Codes
What other systems call cliramitug · ClinicalTrials.gg INT016329
- UNII (FDA) DF9B2M6KQGCLIRAMITUGOne source FDA
- NCI Thesaurus C215729CliramitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DF9B2M6KQG | CLIRAMITUG | One source FDA |
| NCI Thesaurus | C215729 | Cliramitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.